Partner with Us
Join Us in Charting a New Course in Precision Immunotherapies
From Preclinical Promise to Clinical Validation
MabQuest Therapeutics is at a pivotal moment. With MAQ-001 showing promising preclinical efficacy and safety, we are poised to move rapidly in clinical development.
Our strategic roadmap is built on three key pillars:
Safety
Excellent safety profile associated with proven anti-tumor activity.
Read the article
Expanded Indications
Expanded indication in combination with all cancer therapies, without being in competition with conventional anti-PD-1 monotherapy.
Patent-Backed Innovation
Robust worldwide intellectual property portfolio with patent protection for MAQ-001 secured until 2036.
We are actively seeking venture capital and strategic pharmaceutical partners to accelerate our clinical programs and bring transformative therapies to patients worldwide.